Company intelligence / Profile preview

Cato Holding Company

Ownership: Private
Development stage: Other

Overview

Allucent (formerly CATO SMS) is a global biopharmaceutical services company focused on providing comprehensive clinical development and consulting services to small and midsize biopharma clients, particularly those developing complex therapies in areas such as oncology, rare disease, infectious disease, and cell and gene therapy. Allucent was formed through the merger of CATO SMS and Pharm-Olam, followed by a rebranding in May 2022, and now operates with a global workforce, deep scientific expertise, and a full-service model for Phase I-IV clinical research.

Therapeutic areas: ImmunologyNeurologyInfectious DiseasesRare DiseasesOncology
Modalities: Small moleculeBiologicCell and gene therapyVaccineRecombinant protein
Industry: Contract Research Organization

Beyond the preview

Go deeper on Cato Holding Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cato Holding Company.

Explore the full profile